Innova Captab Q2FY27 Revenue at ₹496.3 Cr, Up 30.5%; PAT Jumps 43%
Innova Captab reported strong Q2FY27 results with Revenue from Operations at ₹496.3 crore, up 30.5% YoY. EBITDA grew 29.2% to ₹72.4 crore, and PAT increased 43.0% to ₹42.4 crore. For H1FY27, revenue rose 32.1% to ₹967.2 crore, EBITDA by 31.0% to ₹147.5 crore, and PAT by 42.6% to ₹86.5 crore.
The announcement details strong financial results with substantial percentage growth in revenue and profit, which is a material event for investors and stakeholders.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both the quarter and half-year ended September 30, 2026, indicating a positive financial performance.
Innova Captab Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026, reporting strong growth across key metrics.
For the second quarter of fiscal year 2027 (Q2FY27), the company's Revenue from Operations surged by 30.5% year-on-year to ₹496.3 crores, compared to ₹380.4 crores in Q2FY26. EBITDA increased by 29.2% to ₹72.4 crores, with an EBITDA margin of 14.6%. Profit After Tax (PAT) saw a significant jump of 43.0% to ₹42.4 crores, resulting in a PAT margin of 8.5%.
In the first half of fiscal year 2027 (H1FY27), Revenue from Operations grew by 32.1% to ₹967.2 crores from ₹731.9 crores in H1FY26. EBITDA for the half-year rose by 31.0% to ₹147.5 crores, maintaining an EBITDA margin of 15.3%. PAT for H1FY27 was ₹86.5 crores, a substantial increase of 42.6% from ₹60.7 crores in the previous year, with a PAT margin of 8.9%.
Mr. Vinay Lohariwala, Managing Director, commented on the performance, highlighting the strength of the diversified business model and disciplined execution. He noted the healthy business momentum in CDMO and Branded Generics businesses, driven by a diverse product portfolio and customer engagement. The company is focusing on operational excellence, manufacturing efficiency, and quality, with plans to ramp up the Jammu facility and further strengthen manufacturing capabilities. Going forward, Innova Captab remains committed to enhancing its CDMO positioning, expanding its branded generics presence, and increasing manufacturing capacities, confident in sustaining long-term growth and stakeholder value through strategic capital allocation.
What to do with a filing like this
Innova Captab Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Innova Captab Limited. Read the original for the full detail.